Desmoid Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Desmoid tumor (DT) is a rare type of monoclonal, fibroblastic proliferation that can have an unpredictable clinical course. The World Health Organization (WHO) classifies DT as a "clonal fibroblastic proliferation that arises in the deep soft tissues and is characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize." While DT can occur in multiple areas of the same limb or body part, it typically appears in abdominal, intra-abdominal, and extra-abdominal locations. About 5-10% of DT cases occur in individuals with familial adenomatous polyposis (FAP). CTNNB1 mutations and APC mutations are mutually exclusive in DT. Diagnosis depends on a combination of morphologic and immunohistochemical findings. DT is most often poorly circumscribed on a surgical specimen, featuring a scar-like, whitish-cut surface and ranging in size. Microscopically, a DT is composed of a cytologically bland, at most moderately cellular, infiltrative spindle cell proliferation set in a variably collagenous stroma. Peripheral infiltration of skeletal muscle is often seen.

·       Desmoid tumor (DT) incidence ranges from 5 to 7.5 cases per million population in the USA.

 

Thelansis’s “Desmoid Tumor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Desmoid Tumor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Desmoid Tumor across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Desmoid Tumor Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Desmoid Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Desmoid Tumor, Desmoid Tumor market outlook, Desmoid Tumor competitive landscape, Desmoid Tumor market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)